Control of Cell Cycle and Cell Proliferation
- 1st Edition, Volume 135 - April 11, 2023
- Editor: Rossen Donev
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 5 8 2 2 - 3
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 5 8 2 3 - 0
Control of Cell Cycle and Cell Proliferation, Volume 135 in the Advances in Protein Chemistry and Structural Biology series, presents chapters on a variety topics, including Exp… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteControl of Cell Cycle and Cell Proliferation, Volume 135 in the Advances in Protein Chemistry and Structural Biology series, presents chapters on a variety topics, including Exploiting pivotal mechanisms behind the senescence-like cell cycle arrest, Viral infection on through Cell Cycle Regulation, Analyzing drug resistant mutation in CDK4 gene and identification of potential inhibitors through structure based virtual screening approach, Controlling cell proliferation by targeting CDK6 using drug repurposing approach, The role of the nucleolus in regulating cell cycle, Chromatin regulators in DNA replication and genome stability maintenance during S-phase, Role of macrophage in cancer cell progression and targeted immunotherapies, and much more.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in the Advances in Protein Chemistry and Structural Biology series
- Includes the latest information on Control of Cell Cycle and Cell Proliferation
Scientists and researchers
- Cover
- Title page
- Table of Contents
- Copyright
- Contributors
- Chapter One: Exploiting pivotal mechanisms behind the senescence-like cell cycle arrest in cancer
- Abstract
- 1: Introduction
- 2: Senescence-like cell cycle arrest in cancer
- 3: General signaling pathways engaged in senescence-like cell cycle arrest
- 4: Conclusion
- 5: Future perspective
- References
- Chapter Two: Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting
- Abstract
- 1: Introduction
- 2: Cyclins and cyclin-dependent kinases in cell cycle progression
- 3: Cyclin-dependent kinase inhibitors (CDKIs) in cancer therapeutics
- 4: Conclusion
- Ethical approval and consent to participate
- Consent for publication
- Availability of supporting data
- Competing interests
- References
- Chapter Three: Computational screening and structural analysis of Gly201Arg and Gly201Asp missense mutations in human cyclin-dependent kinase 4 protein
- Abstract
- 1: Introduction
- 2: Materials and methods
- 3: Results and discussion
- 4: Conclusion
- References
- Chapter Four: Controlling cell proliferation by targeting cyclin-dependent kinase 6 using drug repurposing approach
- Abstract
- 1: Introduction
- 2: Methodology
- 3: Results
- 4: Discussion
- 5: Conclusion
- References
- Chapter Five: CDK regulators—Cell cycle progression or apoptosis—Scenarios in normal cells and cancerous cells
- Abstract
- 1: Introduction
- 2: CDK regulators
- 3: Comparison between normal cells and cancerous cells
- 4: CDKI as therapeutics
- 5: Conclusion
- 6: Future prospects
- References
- Chapter Six: Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis
- Abstract
- 1: Introduction
- 2: Aberrant cell cycle checkpoints cooperate with cancer progression
- 3: AMBRA1 destabilizes cyclin D protein
- 4: Immunomodulatory function of cell cycle regulators
- 5: Cell cycle-based targeted cancer therapies
- 6: Targeting CK1ɛ for overcoming resistance to CDK4/6 inhibitors
- 7: Discussion
- Acknowledgment
- References
- Chapter Seven: The role of the nucleolus in regulating the cell cycle and the DNA damage response
- Abstract
- 1: Introduction
- 2: Nucleolus structure
- 3: The nucleolar proteome
- 4: Nucleolar assembly and disassembly during the cell cycle
- 5: The role of the nucleolus in regulating p53-dependent cell cycle events
- 6: p53-independent cell cycle regulation by nucleolar proteins
- 7: Nucleolar stress and DNA repair
- 8: The role of NPM1 in protecting from genomic instability
- 9: The nucleolus and cell death pathways
- 10: Nucleolar proteins in cancer
- 11: Conclusions
- References
- Chapter Eight: Chromatin regulators in DNA replication and genome stability maintenance during S-phase
- Abstract
- 1: Replication of chromatin
- 2: Cellular response to replication stress
- 3: Chromatin factors involved in DNA replication initiation
- 4: Chromatin in the maintenance of DNA replication elongation and replication stress protection
- 5: Chromatin events at stalled forks
- 6: Transcription-induced replication stress
- 7: Exploiting replication stress
- 8: Concluding remarks
- Acknowledgments
- References
- Chapter Nine: Role of macrophages in cancer progression and targeted immunotherapies
- Abstract
- 1: Overview of tumor-associated macrophages
- 2: Polarization of TAMs
- 3: TAMs involvement in tumor progression
- 4: Role of TAMs in immune response
- 5: Cell cycle regulation in TAMs and cancer cells
- 6: Therapies targeting cancer cell cycle progression by targeting TAMs
- 7: Future directions
- References
- Chapter Ten: Therapeutic targets in cancer treatment: Cell cycle proteins
- Abstract
- 1: Introduction
- 2: Tumor cell cycle phase analysis
- 3: Cell-cycle checkpoint
- 4: Targeting cell cycle kinases in cancer therapy
- 5: Role of D-type cyclins in cancer
- 6: Role of cyclin E in cancer
- 7: Role of cyclin B and CDK1 in cancer
- 8: Role of polo-like kinases (Plks) family members in cancer
- 9: Plks in cancer development
- 10: DNA damage checkpoint kinases
- 11: Currently used cyclin inhibitors
- 12: Concluding remarks
- References
- Chapter Eleven: Anti-cancer drug molecules targeting cancer cell cycle and proliferation
- Abstract
- 1: Introduction
- 2: Overview of cell cycle checkpoints
- 3: Disturbance in cancer cell cycle checkpoints
- 4: Anti-cancer drugs
- 5: Drugs that target cell cycle proteins
- 6: Cancer cell proliferation inhibitors
- 7: Conclusion
- References
- Chapter Twelve: Cellular signals integrate cell cycle and metabolic control in cancer
- Abstract
- 1: Growth factors in cancer
- 2: Growth factor signal transduction and biological responses
- 3: Growth factor-dependent signaling and cell cycle progression
- 4: The cell cycle controls the metabolism
- 5: Conclusion
- References
- Chapter Thirteen: Therapeutic targeting and HSC proliferation by small molecules and biologicals
- Abstract
- 1: Introduction
- 2: Cell cycle kinetics of hematopoietic stem cells
- 3: Hematopoietic stem cells expansion technologies
- 4: Small molecule-induced HSC expansion
- 5: Clinical perspective on HSC expansion
- 6: Conclusion
- References
- Chapter Fourteen: Mechanism of cell cycle regulation and cell proliferation during human viral infection
- Abstract
- 1: Introduction
- 2: Cell cycle: An overview
- 3: Brief account of viruses involved in the regulation of the cell cycle
- 4: Mechanistic account of virus mediated cell regulation
- 5: Conclusions
- References
- No. of pages: 542
- Language: English
- Edition: 1
- Volume: 135
- Published: April 11, 2023
- Imprint: Academic Press
- Hardback ISBN: 9780443158223
- eBook ISBN: 9780443158230
RD
Rossen Donev
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.
Affiliations and expertise
Head of Research, MicroPharm Limited, UKRead Control of Cell Cycle and Cell Proliferation on ScienceDirect